Deloitte’s analysis focused on projected returns from the late-stage pipelines of the 12 largest drugmakers by 2009 research and development spending, according to a Jan. 12 news release. Here are four key findings from the report:
- In 2021, return on investment for pharmaceutical research and development rose to 7 percent, from 2.7 percent in 2020. This marks the largest annual increase since Deloitte began releasing its report in 2010.
- The average cost of developing a new drug dropped to $2 billion in 2021, down from $2.4 billion in 2020.
- The estimate for peak sales per asset rose to $521 million in 2021, up from $422 million in 2020.
- The average cycle time for developing a new drug decreased for the first time since 2016. The average cycle time was 6.9 years in 2021, down from 7.14 years in 2020.
